Fusion Biopsy Market Size, Share, Growth Report 2032

Fusion Biopsy Market Size

According to a report from Zion Market Research, the global Fusion Biopsy Market was valued at USD 672.3 Million in 2023 and is projected to hit USD 1553.43 Million by 2032, with a compound annual growth rate (CAGR) of 8.7% during the forecast period 2024-2032. This report explores market strengths, weakness, opportunities, and threats. It also provides valuable insights into the market's growth drivers, challenges, and the future prospects that may emerge in the Fusion Biopsy Market industry over the next decade.

Request Free Sample

Fusion Biopsy Market: Overview

Fusion biopsy is a method that combines images taken by MRI Scan machine & ultrasound for producing comprehensive image of prostrate. Moreover, the procedure makes it easy to observe enlarged abnormal tissues and thus helps in guiding biopsy needle into the tissues with abnormal enlargement.

Furthermore, with help of fusion biopsy, a sample of cell tissues can be extracted from enlarged abnormal tissues and monitored under electron microscope for diagnosing symptoms of cancer. In addition to this, fusion biopsy can detect cancer cell tissues in prostrate that other biopsies can probably miss out. Reportedly, it assists physicians in identification of cancer at initial phase, thereby planning early treatment of the chronic disorder.

Request Free Sample

Fusion Biopsy Market: Growth Drivers

A prominent surge in incidences of prostate cancer has resulted into massive demand for fusion biopsy in recent years. In addition to this, fusion biopsy has ability to localize dominant ailment and accurately classify disease risk. Furthermore, it can rectify drawbacks of systematic biopsies and avoid biopsy of subjects having normal MRI, thereby restricting over detection of indolent lumps.  Apart from this, fusion biopsy assist in targeting candidates with MRI identifying abnormalities, get less false negative reports leading to reduction in number of repeated biopsies, and derive accurate classification of prostate cancer. All these aforementioned aspects will steer growth of fusion biopsy industry over years ahead.

Moreover, growing significance of routine medical interventions has resulted in massive penetration of fusion biopsy in healthcare sector, thereby driving market trends. Apparently, favorable compensation policies pertaining to use of fusion biopsy for detecting prostate cancer will result in massive market demand.

Fusion Biopsy Market: Report Scope

Fusion Biopsy Market: Regional Landscape

Asia Pacific Fusion Biopsy Market To Register Highest CAGR of Nearly 8.7 Over 2024-2032

Growth of fusion biopsy market in Asia Pacific over forecast timeline can be attributed to surge in awareness about prostate cancer among population of region. In addition to this, unhealthy food habits as well as unstructured, undisciplined & inconsistent lifestyle of people in region has further contributed to chronic disorders such as prostate cancer resulting in rise in use of fusion biopsy in healthcare sector. Undoubtedly, a rapid increase in geriatric population susceptible to various kinds of prostrate problems will enlarge scope of fusion biopsy industry in sub-continent. Unmet medical needs of patients in countries such as China, India, and Japan will create new growth avenues for fusion biopsy market in Asia Pacific.

Fusion Biopsy Market: Competitive Landscape

Some of the leading in the global market include

• MedCom
• Focal Healthcare
• ESAOTE SPA
• GeoScan Medical
• KOELIS
• UC-Care Medical Systems Limited.

The global Fusion Biopsy Market is segmented as follows:

By Biopsy Route

• Transrectal
• Transperineal

By End-Use

• Hospitals
• Diagnostic Centers
• Ambulatory Care Centers

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa